The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

US FDA grants fast track designation to DualityBio's next-generation HER3 ADC DB-1310 to treat nonsquamous non-small cell lung cancer: Shanghai Wednesday, July 23, 2025, 14:30 Hrs ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

Q2 2025 Earnings Call Transcript July 16, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

Seventy percent of Asian American and Pacific Islander women diagnosed with lung cancer were non- or never-smokers, ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced it expects topline data in early 2026 from its global Phase 3 FURVENT trial ...